Compare Hinge Health Inc. Class A Common Stock (HNGE) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs NICE Ltd — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.96 (market cap $8.48B), while NICE Ltd trades at $110.41 (market cap $6.90B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and NICE Ltd for 16 Days on average.
| HNGE | NICE | |
|---|---|---|
Market Cap | $8.48B | $6.90B |
Volume | 879,799 | 665,954 |
Sector | Health | Technology |
52-Week High | $105.14 | $136.90 |
52-Week Low | $31.17 | $83.15 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $8.10B | $6.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
NICE stock trades at $114.95, down 0.08% on the day, with a bullish technical signal from moving averages and key support at $113. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.70 exceeding the $2.63 estimate. Revenue reached $2.95 billion in 2025, though net income is projected to decline to $425 million in 2026. Analyst consensus is a Buy with a $124.20 price target, and recent news highlights leadership in AI-driven contact center platforms.
The outlook for NICE is positive, driven by AI revenue growth and a low valuation, but investors face risks from margin compression due to heavy AI investments and competitive pressures. The stock's current price offers a potential 8% upside to the consensus target, supported by institutional buying interest and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
